Sign Up to like & get
recommendations!
2
Published in 2023 at "Drug Development Research"
DOI: 10.1002/ddr.22042
Abstract: A series of imidazodiazepines has been developed that possess reduced sedative liabilities but retain efficacy in anticonvulsant screening models. The latest of these compounds, (5‐(8‐ethynyl‐6‐(pyridin‐2‐yl)‐4H‐benzo[f]imidazole[1,5‐α][1,4]diazepin‐3‐yl) oxazole known as KRM‐II‐81) is currently awaiting advancement into the…
read more here.
Keywords:
comparative anticonvulsant;
krm;
anticonvulsant activity;
anticonvulsant ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "ACS Omega"
DOI: 10.1021/acsomega.2c03029
Abstract: Imidazodiazepine (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-α][1,4]diazepin-3-yl) oxazole or KRM-II-81) is a potentiator of GABAA receptors (a GABAkine) undergoing preparation for clinical development. KRM-II-81 is active against many seizure and pain models in rodents, where it exhibits improved pharmacological properties…
read more here.
Keywords:
krm;
hydrochloride salt;
krm hcl;
salt ... See more keywords